HOME >> BIOLOGY >> NEWS
New approach limits damage after heart attack and improves survival, say Scripps Research scientists

A team led by scientists at The Scripps Research Institute has developed a potential new treatment for heart attacks. The therapy inhibits fluid leakage from cardiac blood vessels following a heart attack and thereby significantly prevents long-term heart damage and improves survival.

"Immediately following a heart attack, blood vessels near the site of injury become leaky, causing fluid accumulation in the healthy area of the heart surrounding the injured site," says Immunology Professor David A. Cheresh, Ph.D., who led the research with postdoctoral fellow Sara Weis, Ph.D at The Scripps Research Institute. This permeability response is devastating to normal heart tissue.

"Until now," continues Cheresh, "nobody has realized the extent to which this leak response damages heart tissue and causes long-term tissue injury. We discovered a way to block this process and thus save heart tissue from irreversible damage."

Using laboratory models that are designed to mimic the pathology of heart attacks in humans, Cheresh, Weis, and their colleagues found that a single dose of a compound designed to block this fluid leakage (which is called edema) can, even if given as late as six hours after the event, drastically reduce tissue injury and increase long-term survival following a heart attack.

A biopharmaceutical company, TargeGen Inc. in San Diego, is finalizing preclinical studies to translate these initial research findings into practical human therapies. Using extensive preclinical models that mirror human heart attacks, TargeGen scientists report that 40 to 60 percent reductions in infarct (tissue injury) size with a small molecule drug that inhibits vascular leak and edema. Based on the encouraging preclinical efficacy and safety studies, TargeGen plans to initiate a combined Phase I/II human clinical trial in the second half of 2004 for patients undergoing an acute heart attack.

In addition to Cheresh and Weis, the team
'"/>

Contact: Jason Bardi
jasonb@scripps.edu
858-784-9254
Scripps Research Institute
15-Mar-2004


Page: 1 2 3 4 5

Related biology news :

1. Belgian researchers explore revolutionary approach to angiogenesis
2. Novel IBD therapeutic approaches reported from Washington Univ., Barcelona, LSU at APS meeting
3. Researchers recommend new approach to combat drug-resistant staph infections
4. U. Iowa muscular dystrophy discovery may lead to new treatment approaches
5. New research suggests therapeutic approach for autoimmune diseases
6. New approach offers potential drug-discovery shortcut
7. Steroid-coated DNA represents new approach to gene delivery
8. Two-drug approach might shorten painful labor, reduce Caesarean sections
9. Death-defying approach devised by Penn scientists to prevent cell apoptosis
10. Smallpox in 50-year-old tissues detected by integrated diagnostics approach
11. One-size-fits-all approach to nutrition recommendations may soon be outdated

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2020)... ... June 24, 2020 , ... eClinical Solutions LLC ... services that accelerate drug development, is collaborating with Karyopharm Therapeutics (Nasdaq: KPTI ... patients with severe COVID-19. This is the first study of an XPO1 inhibitor ...
(Date:6/23/2020)... , ... June 22, 2020 , ... The field of ... ligand binding assays (LBA) have dominated this area. However, the use of mass spectrometry ... , This now necessitates the question “How do you choose which approach to use ...
(Date:6/19/2020)... ... June 16, 2020 , ... The director of stem cell biotechnology ... the stem cell medicine and pharmaceutical industries have easier access to stem cell counting, ... July 5 of this year, Independence Day weekend in the U.S., Asymmetrex is offering ...
Breaking Biology News(10 mins):
(Date:6/23/2020)... ... June 22, 2020 , ... Regen Suppliers, the one stop ... buy three, get the fourth unit free with no limit on the amniotic ... as exosomes, have been a game changer for regenerative therapies. The products are ...
(Date:6/11/2020)... ... , ... PathSensors Inc., a Baltimore biotechnology company, announced today ... funded by the National Institute of Food and Agriculture (NIFA) entitled “Food Safety ... was to engineer and develop a field-deployable instrument for portable pathogen and toxin ...
(Date:5/30/2020)... ... 29, 2020 , ... Medrio, Inc., the leading provider of ... enabled Cytovale, Inc., a medical technology company dedicated to revolutionizing diagnostics for conditions ... patient in (FPI) in just seven days. The Cytovale technology will allow patients ...
(Date:5/21/2020)... ... May 21, 2020 , ... Threats ... cause long-term harm , Contrary to conventional wisdom that says the coronavirus pandemic ... many companies will emerge from the pandemic commercially weaker, dealing with delays in ...
Breaking Biology Technology:
Cached News: